# To Challenge the Status Quo: Staging a Teach-In on Access to Medicines

In mid-February the Harvard Financial Analysts Club invited Martin Shkreli to campus to give a talk on “healthcare and investing.” This worried a significant portion of Harvard students on many fronts. I write here from the perspective of the Global Health & AIDS Coalition (GHAC).

Martin Shkreli, perhaps better known as Pharma Bro, earned himself a mix of infamy and admiration after hiking the price of Daraprim– a drug used to treat toxoplasmosis (a symptom in immunocompromised patients) – from $13.50 to$750 overnight. Shkreli’s investing approach can be broken down quite simply...